Primary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin (PROP-LT)
Preventing Recurrence of Primary Sclerosing Cholangitis After Liver Transplant (PROP-LT): a Phase 1, Open-label, Controlled Study of Oral Vancomycin
Primary Objective:
- To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily [TID]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC).
Secondary Objectives:
- To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC.
- To assess vancomycin resistant enterococcus (VRE) colonization status over time.
- To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function.
- To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool.
- To assess impact of oral vancomycin on liver-related biochemical markers.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, often associated with inflammatory bowel disease (IBD). A subset of patients ultimately require liver transplantation, yet rPSC occurs in approximately 25-30% of transplant recipients and can lead to graft failure and re-transplantation.
There is increasing evidence that the gut microbiome plays a role in PSC and rPSC pathogenesis. Altered microbiota composition has been identified in patients with PSC. This association is true not only in patients with PSC compared to controls, but also in patients with PSC-IBD compared to patients with IBD-no PSC, indicating a true association with the liver disease itself. Compared to patients with PSC who do not develop post-transplant recurrence, patients who will develop rPSC have altered microbiome composition at the time of liver transplant. Microbial manipulation-including oral antibiotics, fecal microbiota transplantation, and other strategies-has emerged as a potential therapeutic avenue in native liver PSC. In particular, there is mounting interest in oral vancomycin (OV) as a treatment for PSC, as several case reports/case series and a few small trials have demonstrated that OV is associated with reductions in alkaline phosphatase and other markers of liver injury. This effect may be mediated by the impact of OV on bile acid metabolism, short-chain fatty acid production, and/or prevalence of specific bacterial taxa such as Enterococcus gallinarum, a vancomycin-sensitive microbe that has been associated with PSC.
In case reports of patients with post-transplant rPSC, use of OV was also associated with improvement in biochemical markers of liver disease activity. Liver transplant recipients represent a specialized population with unique medication exposures and microbiome composition. While short course of OV are safely used in liver transplant recipients for the treatment of Clostridioides difficile, no prospective study has systematically examined safety, tolerability, microbiome changes, and hepatic effects of OV in liver transplant recipients transplanted for PSC.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Rebecca Yeh, BA
- Phone Number: 2123053839
- Email: ry2334@cumc.columbia.edu
Study Contact Backup
- Name: Thresiamma (Theresa) Lukose, PharmD
- Phone Number: 2123053839
- Email: tt2103@cumc.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
Contact:
- Rebecca Yeh
- Email: ry2334@cumc.columbia.edu
-
Principal Investigator:
- Yael Nobel, MD, MS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Age ≥ 18 years
-
Ability to provide written, informed consent.
-
History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation)
-
Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiogram [PTC]), liver histology, and/or clinician judgment
-
Subjects with or without IBD may be enrolled. IBD diagnosis with a minimum disease duration of 6 months as assessed by endoscopy/histology. IBD should be in clinical remission or mildly active according to accepted clinical scores and/or clinician judgment.
-
Stable liver graft function, as determined by ALL of the following criteria:
- No episodes of acute rejection within 6 months prior to enrollment, based on liver histology and/or clinical signs or symptoms
- No episodes of cholangitis within 6 months prior to study enrollment, based on positive bacterial cultures, compatible imaging, and/or clinical signs or symptoms
- No intervention for biliary obstruction (e.g. ERCP, PTC, surgical intervention) within 6 months prior to study enrollment.
- Stable liver biochemistries within 6 months prior to study enrollment, as determined by: ALP <5x ULN
- Absence of histologic or imaging findings suggestive of cirrhosis
Exclusion Criteria:
- History of colon resection at any time prior to study enrollment or presence of ileal/colonic diversion within 12 months prior to study enrollment
- Documented VRE infection within 12 months prior to study enrollment
- Documented C. difficile infection within 3 months prior to study enrollment
- Systemic antibiotic exposure within 3 months prior to study enrollment
- Change in any transplant or IBD-related immunosuppression or its dosing within 30 days prior to study enrollment
- Currently taking oral vancomycin
- Allergy or intolerance to vancomycin
- Treatment with any investigational drug within 3 months prior to study enrollment
- Severe renal dysfunction (eGFR <30 mL/min/1.73 m²) or on dialysis
- Any active malignancy
- Pregnant or breastfeeding Page 8
- Any condition that, in the investigator's judgment, would make participation unsafe or interfere with adherence (e.g., severe frailty, uncontrolled psychiatric disease, inability to adhere to TID dosing)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Study Arm - Oral Vancomycin
Patients in study arm will be assigned to receive study drug. |
Vancomycin 250 mg orally three times per day (TID, 750 mg/day), with doses spaced approximately 8 hours apart (e.g., morning, midday, evening), for a total duration of 4 weeks. Missed doses will not be made up; participants will be instructed to resume the next scheduled dose. Vancomycin is a glycopeptide antibiotic supplied as oral capsules 250 mg. It acts by inhibiting bacterial cell wall synthesis. Oral vancomycin is minimally absorbed in patients with intact gut mucosa, resulting in high intraluminal concentrations.
Other Names:
|
|
No Intervention: Control Arm - No Drug
Patients in control arm will be assigned to receive no drug. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients experiencing any treatment-related adverse event of grade ≥2
Time Frame: Up to 4 weeks
|
This is to evaluate safety of a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The assessments will be using CTCAE v6.0 grading in the study arm receiving vancomycin compared to the control arm. Percentage (or the number) of study participants who experience related AEs of grade > or = 2 will be tallied and calculated. |
Up to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in patient-reported short form-36 symptom questionnaire score
Time Frame: Baseline to 4 weeks, baseline to 8 weeks
|
To determine tolerability to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The clinical outcomes will be recorded using the SF-36 questionnaire. SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. Items are scored 0-100 with higher scores indicating a more favorable health state. |
Baseline to 4 weeks, baseline to 8 weeks
|
|
Proportion of participants who complete 4 weeks of oral vancomycin with ≥ 80% of planned doses
Time Frame: Up to 4 weeks
|
To determine adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The completion of study treatment will be defined, assessed and tallied by self-report and/or pill count. |
Up to 4 weeks
|
|
Proportion of participants with VRE Colonization Status
Time Frame: Baseline, Week 4, and Week 8
|
The status will be determined by the presence or absence of vancomycin-resistant Enterococcus (VRE) colonization based on stool sample or rectal swab testing. The result will be positive or negative. The participants with positive results will be tallied. |
Baseline, Week 4, and Week 8
|
|
Proportion of participants with changes in Stool Microbiome Composition and Diversity
Time Frame: Baseline to 4 weeks, Baseline to 8 weeks
|
Proportion of participants with change in microbiome composition from baseline to subsequent timepoints as assessed by alpha and beta diversity, differential taxa abundance, and/or changes in genes and gene pathways. |
Baseline to 4 weeks, Baseline to 8 weeks
|
|
Proportion of participants with change in liver-related biochemical markers
Time Frame: Baseline and 4 weeks, Baseline and 8 weeks
|
Participants with change in ALP, ALT, and/or GGT (particularly a decrease in ALP) will be tallied and calculated. |
Baseline and 4 weeks, Baseline and 8 weeks
|
|
Proportion of participants with change in microbial metabolite concentrations.
Time Frame: Baseline and 4 weeks, Baseline and 8 weeks
|
Participants with changes in microbial metabolite such as short chain fatty acids and bile acids will be tallied and calculated. |
Baseline and 4 weeks, Baseline and 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yael R Nobel, M.D., M.S., Assistant Professor of Medicine Center for Liver Disease and Transplantation
Publications and helpful links
General Publications
- Bowlus CL, Arrive L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702. doi: 10.1002/hep.32771. Epub 2022 Oct 20. No abstract available.
- Bogatic D, Bryant RV, Lynch KD, Costello SP. Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2023 Jan;57(1):23-36. doi: 10.1111/apt.17251. Epub 2022 Nov 2.
- Hole MJ, Jorgensen KK, Holm K, Braadland PR, Meyer-Myklestad MH, Medhus AW, Reikvam DH, Gotz A, Grzyb K, Boberg KM, Karlsen TH, Kummen M, Hov JR. A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation. Hepatology. 2023 Mar 1;77(3):715-728. doi: 10.1002/hep.32773. Epub 2023 Feb 17.
- Quraishi MN, Sergeant M, Kay G, Iqbal T, Chan J, Constantinidou C, Trivedi P, Ferguson J, Adams DH, Pallen M, Hirschfield GM. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut. 2017 Feb;66(2):386-388. doi: 10.1136/gutjnl-2016-311915. Epub 2016 Apr 19. No abstract available.
- Visseren T, Fuhler GM, Erler NS, Nossent YRA, Metselaar HJ, IJzermans JNM, Darwish Murad S, Peppelenbosch MP. Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant - a pilot study. Transpl Int. 2020 Nov;33(11):1424-1436. doi: 10.1111/tri.13692. Epub 2020 Jul 26.
- Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):61-7. doi: 10.1097/MPG.0b013e31816fee95.
- Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, Nadeau KC, Cox KL. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2013 Feb;33(2):397-406. doi: 10.1007/s10875-012-9801-1. Epub 2012 Oct 9.
- Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013 Mar;37(6):604-12. doi: 10.1111/apt.12232. Epub 2013 Feb 5.
- Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study. J Gastrointestin Liver Dis. 2016 Dec;25(4):457-464. doi: 10.15403/jgld.2014.1121.254.rah.
- Ali AH, Damman J, Shah SB, Davies Y, Hurwitz M, Stephen M, Lemos LM, Carey EJ, Lindor KD, Buness CW, Alrabadi L, Berquist WE, Cox KL. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020 Aug;55(8):941-950. doi: 10.1080/00365521.2020.1787501. Epub 2020 Jul 7.
- Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, Yamaguchi A, Kanamori M, Kamada N, Hattori M, Ashida H, Sakamoto M, Atarashi K, Narushima S, Yoshimura A, Honda K, Sato T, Kanai T. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019 Mar;4(3):492-503. doi: 10.1038/s41564-018-0333-1. Epub 2019 Jan 14.
- Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transplant. 2013;2013:314292. doi: 10.1155/2013/314292. Epub 2013 Feb 24.
- Hey P, Lokan J, Johnson P, Gow P. Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep. 2017 Sep 25;2017:bcr2017221165. doi: 10.1136/bcr-2017-221165.
- Annavajhala MK, Gomez-Simmonds A, Macesic N, Sullivan SB, Kress A, Khan SD, Giddins MJ, Stump S, Kim GI, Narain R, Verna EC, Uhlemann AC. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. Nat Commun. 2019 Oct 17;10(1):4715. doi: 10.1038/s41467-019-12633-4.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ACYY2503
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.